Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria

Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement-mediated intravascular hemolysis due to the absence of complement regulators CD55 and CD59 on affected erythrocytes. Danicopan is a first-in-class oral proximal, complement alternative pathway factor D inhibitor. Therapeutic fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Risitano, Antonio M., Kulasekararaj, Austin G., Lee, Jong Wook, Maciejewski, Jaroslaw P., Notaro, Rosario, Brodsky, Robert, Huang, Mingjun, Geffner, Michael, Browett, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634185/
https://www.ncbi.nlm.nih.gov/pubmed/33121236
http://dx.doi.org/10.3324/haematol.2020.261826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634185/
https://www.ncbi.nlm.nih.gov/pubmed/33121236
http://dx.doi.org/10.3324/haematol.2020.261826

Ejemplares similares